EMA accepts Takeda/Millennium's Adcetris for review
This article was originally published in Scrip
Executive Summary
The European Medicines Agency has accepted a filing from Takeda' Millennium unit for marketing authorisation of its antibody-drug conjugate (ADC), Adcetris (brentuximab vedotin), for the treatment of relapsed or refractory Hodgkin lymphoma (HL) as well as relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).